MX2020013059A - Inhibidores de calicreina plasmatica humana. - Google Patents

Inhibidores de calicreina plasmatica humana.

Info

Publication number
MX2020013059A
MX2020013059A MX2020013059A MX2020013059A MX2020013059A MX 2020013059 A MX2020013059 A MX 2020013059A MX 2020013059 A MX2020013059 A MX 2020013059A MX 2020013059 A MX2020013059 A MX 2020013059A MX 2020013059 A MX2020013059 A MX 2020013059A
Authority
MX
Mexico
Prior art keywords
plasma kallikrein
human plasma
compounds
kallikrein inhibitors
inhibitors
Prior art date
Application number
MX2020013059A
Other languages
English (en)
Spanish (es)
Inventor
Pravin L Kotian
Yarlagadda S Babu
Minwan Wu
Venkat R Chintareddy
Weihe Zhang
V Satish Kumar
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of MX2020013059A publication Critical patent/MX2020013059A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2020013059A 2014-03-07 2015-03-09 Inhibidores de calicreina plasmatica humana. MX2020013059A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461949808P 2014-03-07 2014-03-07
US201461981515P 2014-04-18 2014-04-18
PCT/US2015/019535 WO2015134998A1 (en) 2014-03-07 2015-03-09 Human plasma kallikrein inhibitors

Publications (1)

Publication Number Publication Date
MX2020013059A true MX2020013059A (es) 2022-10-07

Family

ID=54055948

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020013059A MX2020013059A (es) 2014-03-07 2015-03-09 Inhibidores de calicreina plasmatica humana.
MX2016011468A MX377845B (es) 2014-03-07 2015-03-09 Inhibidores de calicreína plasmática humana.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016011468A MX377845B (es) 2014-03-07 2015-03-09 Inhibidores de calicreína plasmática humana.

Country Status (33)

Country Link
US (14) US10125102B2 (enExample)
EP (4) EP3113772B8 (enExample)
JP (4) JP6574435B2 (enExample)
KR (2) KR102510427B1 (enExample)
CN (2) CN106257976B (enExample)
AU (3) AU2015226855C1 (enExample)
BR (1) BR112016020199A8 (enExample)
CA (2) CA3164693A1 (enExample)
CY (2) CY1123810T1 (enExample)
DK (2) DK3113772T3 (enExample)
EA (1) EA036251B1 (enExample)
ES (3) ES2836373T3 (enExample)
FR (1) FR21C1048I2 (enExample)
HR (2) HRP20201916T1 (enExample)
HU (3) HUE060660T2 (enExample)
IL (2) IL280785B2 (enExample)
LT (3) LT3113772T (enExample)
LU (1) LUC00233I2 (enExample)
MA (1) MA53399B1 (enExample)
MX (2) MX2020013059A (enExample)
MY (1) MY199131A (enExample)
NL (1) NL301142I2 (enExample)
NO (1) NO2022046I1 (enExample)
NZ (2) NZ762034A (enExample)
PH (1) PH12016501750B1 (enExample)
PL (2) PL3828173T3 (enExample)
PT (2) PT3828173T (enExample)
RS (2) RS63763B1 (enExample)
SG (2) SG10202001795XA (enExample)
SI (1) SI3113772T1 (enExample)
SM (2) SMT202100031T1 (enExample)
WO (1) WO2015134998A1 (enExample)
ZA (1) ZA201606320B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
ES2784841T3 (es) 2014-01-31 2020-10-01 Bristol Myers Squibb Co Macrociclos con grupos aromáticos P2' como inhibidores del factor XIa
NO2760821T3 (enExample) 2014-01-31 2018-03-10
CA3164693A1 (en) 2014-03-07 2015-09-11 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
JP6526796B2 (ja) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｘｉａ阻害剤であるジアミドマクロ環
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
SG10202003705WA (en) 2015-10-01 2020-06-29 Biocryst Pharm Inc Human plasma kallikrein inhibitors
MD3464271T2 (ro) 2016-05-31 2020-08-31 Kalvista Pharmaceuticals Ltd Derivați de pirazol în calitate de inhibitori ai kaliсreinei plasmatice
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
HUE057912T2 (hu) 2017-11-29 2022-06-28 Kalvista Pharmaceuticals Ltd Plazma kallikrein inhibitort tartalmazó dózisformák
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
JP7538113B2 (ja) 2018-08-20 2024-08-21 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
UY38438A (es) * 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3953395A4 (en) * 2019-04-08 2023-01-18 Biocryst Pharmaceuticals, Inc. PLASMACALLICREIN INHIBITORS AND METHODS OF USE THEM IN EYE DISEASES
WO2021025969A1 (en) 2019-08-02 2021-02-11 Teva Pharmaceuticals International Gmbh Solid state forms of berotralstat
UA130182C2 (uk) * 2019-08-06 2025-12-10 Байокріст Фармасьютикалз, Інк. Синтез інгібітора плазмового калікреїну в технологічному обсязі
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
EP4017850A1 (en) * 2019-08-21 2022-06-29 Kalvista Pharmaceuticals Limited Enzyme inhibitors
TW202144331A (zh) * 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
EP4116299A4 (en) 2020-03-04 2024-03-27 Medshine Discovery Inc. HETEROCYCLIC COMPOUND
JP7776453B2 (ja) * 2020-06-16 2025-11-26 メルク・シャープ・アンド・ドーム・エルエルシー 血漿カリクレイン阻害剤
KR20230038526A (ko) * 2020-07-10 2023-03-20 머크 샤프 앤드 돔 엘엘씨 혈장 칼리크레인 억제제
WO2022060842A1 (en) * 2020-09-15 2022-03-24 The Trustees Of Columbia University In The City Of New York Systems and methods for predicting graft dysfunction with exosome proteins
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法
WO2025122555A1 (en) * 2023-12-05 2025-06-12 Valo Health, Inc. S1p 1 receptor agonists and uses thereof

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
DE3633840A1 (de) 1986-10-04 1988-04-14 Hoechst Ag Phenylpyrazolcarbonsaeurederivate, ihre herstellung und verwendung als pflanzenwachstumsregulatoren und safener
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
DE69110787T2 (de) 1990-02-28 1996-04-04 Medtronic, Inc., Minneapolis, Minn. Intraluminale prothese mit wirkstoffeluierung.
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
NZ336162A (en) * 1996-12-23 2000-09-29 Du Pont Pharm Co pyrrole, tetrazole or pyrazole derivatives useful as factor Xa inhibitors
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
HRP980334A2 (en) * 1997-06-19 1999-04-30 Mimi Lifen Quan INHIBITORS OF FACTOR Xa WITH A NEUTRAL P1 SPECIFICITY GROUP
ZA985247B (en) * 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
EP1042299A1 (en) * 1997-12-22 2000-10-11 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
US6271237B1 (en) * 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
KR100659007B1 (ko) * 1999-02-10 2007-02-28 미츠비시 웰파마 가부시키가이샤 아미드 화합물 및 그 의약으로서의 용도
AU4327600A (en) 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Aryl sulfonyls as factor xa inhibitors
US20010044445A1 (en) 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6329527B1 (en) 1999-10-21 2001-12-11 Bristol-Myers Squibb Pharma Company Synthesis of 1,3,5-trisubstituted pyrazoles
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
PL201530B1 (pl) 2000-06-27 2009-04-30 L V A T Lab Sa Karbaminiany pochodne aryloalkiloamin i zastosowanie karbaminianów pochodnych aryloalkiloamin
EP1366045A2 (en) 2000-09-22 2003-12-03 Bristol-Myers Squibb Pharma Company Efficient process for the preparation of a factor xa inhibitor
MXPA03009311A (es) 2001-04-12 2004-02-12 Hoffmann La Roche Derivados de dihidro-benzo[b][1,4]diazepin-2-ona como antagonistas ii del receptor metabotropico de glutamato (mglur2).
MY142967A (en) 2001-08-13 2011-01-31 Du Pont Method for controlling particular insect pests by applying anthranilamide compounds
AU2002319814A1 (en) * 2001-08-13 2003-03-03 E.I. Du Pont De Nemours And Company Substituted 1h-dihydropyrazoles, their preparation and use
TW200724033A (en) 2001-09-21 2007-07-01 Du Pont Anthranilamide arthropodicide treatment
JP2005504084A (ja) * 2001-09-21 2005-02-10 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺虫性ジアミド
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
TW200303309A (en) 2001-12-04 2003-09-01 Bristol Myers Squibb Co Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors
EP1513817A1 (en) 2002-05-24 2005-03-16 Takeda Pharmaceutical Company Limited 1, 2-azole derivatives with hypoglycemic and hypolipidemic activity
MXPA04012214A (es) * 2002-06-13 2005-02-25 Du Pont Insecticidas de pirazolcarboxamida.
DE10229070A1 (de) * 2002-06-28 2004-01-15 Merck Patent Gmbh Phenylderivate 5
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
BRPI0407088A (pt) 2003-01-28 2006-01-24 Aventis Pharma Sa Produtos n-aril-heteroaromáticos, composições contendo os mesmos e seu uso
AU2004270733B2 (en) 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
WO2005094805A1 (ja) * 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
JP2007532661A (ja) 2004-04-13 2007-11-15 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー アントラニルアミド殺虫剤
WO2005113522A1 (en) 2004-05-07 2005-12-01 Janssen Pharmaceutica, N.V. Azole carboxamide inhibitors of bacterial type iii protein secretion systems
US20060069270A1 (en) 2004-09-27 2006-03-30 Rafael Shapiro Process for the preparation of 1,3,5-trisubstituted pyrazoles via [3+2] cycloaddition
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
ES2413442T3 (es) 2004-11-18 2013-07-16 E. I. Du Pont De Nemours And Company Insecticidas de antranilamida
EP1820795A4 (en) * 2004-12-07 2010-10-20 Toyama Chemical Co Ltd NEW ANTHRANILIC ACID DERIVATIVE OR SALT FROM IT
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
GB0516703D0 (en) 2005-08-15 2005-09-21 Syngenta Participations Ag Novel insecticides
JP5186751B2 (ja) * 2005-10-14 2013-04-24 住友化学株式会社 ヒドラジド化合物およびその有害生物防除用途
BRPI0617221B1 (pt) 2005-10-14 2016-07-12 Sumitomo Chemical Co composto de hidrazida, seu uso, pesticida e método de controlar uma peste
PE20070795A1 (es) 2005-10-28 2007-08-24 Lilly Co Eli Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
ATE525072T1 (de) 2006-02-09 2011-10-15 Athersys Inc Pyrazole zur behandlung von adipositas und anderen zns-erkrankungen
NZ573573A (en) * 2006-05-16 2011-10-28 Boehringer Ingelheim Int Substituted prolinamides, production thereof and their use as drugs
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
US7625944B2 (en) 2006-07-31 2009-12-01 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20120225057A1 (en) 2006-10-11 2012-09-06 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
JP2010509349A (ja) 2006-11-03 2010-03-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
AU2007333194A1 (en) * 2006-12-08 2008-06-19 Exelixis, Inc. LXR and FXR modulators
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
CN101298451B (zh) 2007-04-30 2013-01-30 中国中化股份有限公司 苯甲酰胺类化合物及其应用
WO2008134969A1 (fr) 2007-04-30 2008-11-13 Sinochem Corporation Composés benzamides et leurs applications
CA2747035C (en) * 2008-12-18 2017-01-24 Bayer Cropscience Ag Tetrazole substituted anthranilic acid amides as pesticides
CN102365278B (zh) 2009-03-26 2015-05-06 先正达参股股份有限公司 杀虫化合物
US8946204B2 (en) 2009-05-07 2015-02-03 Gruenenthal Gmbh Substituted phenylureas and phenylamides as vanilloid receptor ligands
KR20120120237A (ko) 2009-12-18 2012-11-01 액티브사이트 파마슈티칼즈, 인크. 혈장 칼리크레인 억제제의 전구약물
US8815896B2 (en) 2010-02-01 2014-08-26 The Institute Of Cancer Research: Royal Cancer Hospital 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
JPWO2011118818A1 (ja) 2010-03-26 2013-07-04 味の素株式会社 アミジノアニリン誘導体
CN102285963B (zh) 2010-06-21 2014-04-09 中国中化股份有限公司 3-甲氧基吡唑酰胺类化合物及其应用
MX2013002011A (es) 2010-08-20 2013-03-25 Gruenenthal Gmbh Derivados ciclicos de carboxamida y urea sustituidos como ligandos del receptor vainiloide.
BR112013010768A2 (pt) 2010-11-10 2016-07-12 Gruenenthal Gmbh derivados de ureia e carboxamida substituídos por heteroaromáticos como ligantes dos receptores vaniloides
US9284298B2 (en) 2011-04-11 2016-03-15 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
US8691861B2 (en) * 2011-04-13 2014-04-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2013036232A2 (en) 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
AR088799A1 (es) 2011-11-09 2014-07-10 Gruenenthal Gmbh Derivados de carboxamida y urea a base de pirazolilos sustituidos que contienen una porcion fenilo sustituida con un grupo que contiene so₂ como ligandos del receptor de vanilloide
CN103467380B (zh) 2013-09-29 2015-06-24 南开大学 一类取代苯基吡唑酰胺衍生物及其制备方法和应用
CA3164693A1 (en) 2014-03-07 2015-09-11 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
UA130182C2 (uk) 2019-08-06 2025-12-10 Байокріст Фармасьютикалз, Інк. Синтез інгібітора плазмового калікреїну в технологічному обсязі

Also Published As

Publication number Publication date
US11203574B2 (en) 2021-12-21
JP6574435B2 (ja) 2019-09-11
US20250257040A1 (en) 2025-08-14
US10689346B2 (en) 2020-06-23
JP2017507160A (ja) 2017-03-16
US20250270171A1 (en) 2025-08-28
ES2932406T3 (es) 2023-01-18
ES3039514T3 (en) 2025-10-22
US20180258049A1 (en) 2018-09-13
US20210047276A1 (en) 2021-02-18
SG11201607267SA (en) 2016-09-29
EP3113772A1 (en) 2017-01-11
US20240150295A1 (en) 2024-05-09
HUS2100045I1 (hu) 2021-11-29
PT3113772T (pt) 2020-12-15
EP3113772B1 (en) 2020-09-09
EP4663636A2 (en) 2025-12-17
FR21C1048I1 (enExample) 2021-12-10
CY1123810T1 (el) 2022-03-24
CY2021029I2 (el) 2022-03-24
HRP20221373T1 (hr) 2023-01-06
PL3113772T3 (pl) 2021-04-06
CA2941380C (en) 2022-09-06
CA3164693A1 (en) 2015-09-11
RS63763B1 (sr) 2022-12-30
PH12016501750B1 (en) 2023-08-16
AU2020260400B2 (en) 2022-08-11
IL247518A0 (en) 2016-11-30
PL3828173T3 (pl) 2022-12-19
US20210047275A1 (en) 2021-02-18
KR102510427B1 (ko) 2023-03-14
CN106257976A (zh) 2016-12-28
AU2022259742B2 (en) 2024-09-05
PH12016501750A1 (en) 2016-11-21
SMT202100031T1 (it) 2021-03-15
FR21C1048I2 (fr) 2022-09-30
ES2836373T3 (es) 2021-06-24
US20170073314A1 (en) 2017-03-16
US20240150296A1 (en) 2024-05-09
US11192861B2 (en) 2021-12-07
LTC3113772I2 (enExample) 2023-06-26
US12116346B2 (en) 2024-10-15
IL280785A (en) 2021-04-29
JP6915003B2 (ja) 2021-08-04
IL280785B1 (en) 2024-05-01
MY199131A (en) 2023-10-17
MX2016011468A (es) 2017-01-23
US12162838B2 (en) 2024-12-10
PT3828173T (pt) 2022-12-05
US10125102B2 (en) 2018-11-13
US11230530B2 (en) 2022-01-25
IL247518B (en) 2021-02-28
AU2020260400A1 (en) 2020-11-26
BR112016020199A2 (pt) 2017-08-15
CY2021029I1 (enExample) 2022-03-24
ZA201606320B (en) 2025-03-26
CN113307772B (zh) 2024-06-28
IL280785B2 (en) 2024-09-01
AU2015226855C1 (en) 2021-02-11
SMT202300002T1 (it) 2023-03-17
US20180354906A1 (en) 2018-12-13
HRP20201916T1 (hr) 2021-01-22
EP3113772A4 (en) 2017-08-30
EA201691803A1 (ru) 2017-02-28
US20230094305A1 (en) 2023-03-30
EP4180424A1 (en) 2023-05-17
EP3828173A1 (en) 2021-06-02
NO2022046I1 (no) 2022-11-07
AU2015226855B2 (en) 2020-09-03
US10329260B2 (en) 2019-06-25
CN113307772A (zh) 2021-08-27
AU2022259742A1 (en) 2022-12-01
EP4180424B1 (en) 2025-06-25
EP3113772B8 (en) 2020-11-25
HUE060660T2 (hu) 2023-04-28
EP3828173B1 (en) 2022-08-31
US11708332B2 (en) 2023-07-25
HUE052668T2 (hu) 2021-05-28
LUC00233I2 (enExample) 2025-02-03
US20230100082A1 (en) 2023-03-30
LT3828173T (lt) 2022-11-10
KR102736869B1 (ko) 2024-12-02
JP2023181543A (ja) 2023-12-21
DK3828173T3 (da) 2022-11-07
MA53399B1 (fr) 2022-10-31
SI3113772T1 (sl) 2021-01-29
US11708333B2 (en) 2023-07-25
MA53399A (fr) 2021-06-02
LT3113772T (lt) 2020-12-28
JP2021169499A (ja) 2021-10-28
MX377845B (es) 2025-03-11
LTPA2021524I1 (enExample) 2021-11-10
US20230056538A1 (en) 2023-02-23
DK3113772T3 (da) 2020-12-07
JP2019206588A (ja) 2019-12-05
RS61159B1 (sr) 2021-01-29
US20190322626A1 (en) 2019-10-24
US10633345B2 (en) 2020-04-28
US20210078952A1 (en) 2021-03-18
NZ724250A (en) 2022-02-25
NZ762034A (en) 2022-02-25
SG10202001795XA (en) 2020-04-29
AU2015226855A1 (en) 2016-10-13
KR20160130254A (ko) 2016-11-10
US11685721B2 (en) 2023-06-27
CN106257976B (zh) 2021-02-02
BR112016020199A8 (pt) 2021-07-20
WO2015134998A1 (en) 2015-09-11
NL301142I1 (enExample) 2021-11-03
NL301142I2 (nl) 2021-12-09
KR20230042384A (ko) 2023-03-28
CA2941380A1 (en) 2015-09-11
EA036251B1 (ru) 2020-10-20

Similar Documents

Publication Publication Date Title
ZA201606320B (en) Human plasma kallikrein inhibitors
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
SG10201811384TA (en) Mnk inhibitors and methods related thereto
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX381342B (es) Compuestos terapeuticos inhibidores.
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
HK1217092A1 (zh) 治疗性化合物及其用途
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
WO2016004413A3 (en) Gls1 inhibitors for treating disease
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
PH12015501223A1 (en) Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
NZ780408A (en) Human plasma kallikrein inhibitors
EA202091668A2 (ru) Ингибиторы калликреина плазмы человека
MX2019014773A (es) Inhibidores de ccl2.